Bausch Health vs Eli Lilly: Founders, CEOs and History
Bausch Health was founded in 1994 by Eugene Melnyk, Milan Panic and is led by Thomas J. Appio. Eli Lilly was founded in 1876 by Colonel Eli Lilly and is led by David A. Ricks.
Company facts
Bausch Health
- Founded
- 1994
- Headquarters
- Laval, Quebec, Canada
- Current CEO
- Thomas J. Appio
- Employees
- 20,300
Eli Lilly
- Founded
- 1876
- Headquarters
- Indianapolis, Indiana
- Current CEO
- David A. Ricks
- Employees
- 50,000
Founders
Bausch Health
Eugene Melnyk
Eugene Melnyk built Biovail into Canada's largest publicly traded pharmaceutical company, with revenue growing from about $19M in 1995 to roughly $1.07B in 2006.
Milan Panic
Milan Panic ran ICN Pharmaceuticals for four decades and made it known for the broad-spectrum antiviral ribavirin, sold as Virazole.
Eli Lilly
Colonel Eli Lilly
Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own.
CEOs and their tenures
Bausch Health
- J. Michael Pearson2008–2016
Former Chief Executive Officer
Pearson, a former McKinsey director, became chief executive of Valeant Pharmaceuticals effective February 1, 2008 and ran the company through the September 2010 merger with Canada's Biovail until early May 2016.
Source - Joseph C. Papa2016–2022
Former Chief Executive Officer
Papa, previously chief executive of Perrigo, was named chairman and CEO in April 2016 and took over in early May 2016, inheriting about $30B of debt, an SEC investigation and congressional scrutiny of Valeant-era drug pricing.
Source - Thomas J. Appio2022–present
Chief Executive Officer
Appio became chief executive officer and a director in May 2022, succeeding Joseph Papa.
Source
Eli Lilly
- Randall L. Tobias1993–1998
Chairman and Chief Executive Officer
Lilly launched Zyprexa and Humalog under him. Sidney Taurel succeeded him in 1998.
Source - Sidney Taurel1998–2008
Former Chair and CEO
Taurel's focus on targeted, personalized medicine anticipated the future direction of the pharmaceutical industry, shifting the company's research paradigm toward more precise and effective treatments.
Source - John C. Lechleiter2008–2016
Chairman, President and CEO
Lilly restructured and launched new products during his tenure. David Ricks became chief executive in 2017.
Source - David A. Ricks2017–present
Chair and Chief Executive Officer
Ricks's aggressive restructuring and cultural overhaul have been widely credited with revitalizing Eli Lilly's pipeline and driving a notable period of financial growth and market capitalization expansion.
Source
Timeline: Bausch Health and Eli Lilly side by side
1876Eli Lilly
Eli Lilly Founded
Colonel Eli Lilly founds the company in Indianapolis.
1923Eli Lilly
Insulin Commercialization
Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.
1950Eli Lilly
Antibiotic Expansion
The company expands through antibiotics and broader prescription medicines.
1959Bausch Health
Milan Panic founds ICN Pharmaceuticals
Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.
1982Eli Lilly
Humulin Approved
Lilly introduces Humulin, one of the first recombinant DNA human insulin products.
1994Bausch Health
Biovail Corporation International formed in Canada
On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.
2003Bausch Health
ICN renames itself Valeant Pharmaceuticals
ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.
2008Bausch Health
J. Michael Pearson becomes chief executive
Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.
2010Bausch Health
Biovail and Valeant complete their merger
The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.
2011Bausch Health
Ortho Dermatologics bought from Johnson and Johnson
Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.
2013Bausch Health
Bausch + Lomb acquired for $8.7 billion
Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.
2015Bausch Health
Salix acquisition closes at about $11.1 billion
Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.
2015Bausch Health
Drug pricing and Philidor scandal breaks
Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.
2016Bausch Health
Joseph Papa replaces Pearson as chief executive
Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.
2017Bausch Health
Skincare brands and Dendreon sold to cut debt
Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.
2017Eli Lilly
David Ricks Becomes CEO
David A. Ricks becomes Chair, President, and CEO.
2018Bausch Health
Company renamed Bausch Health Companies Inc.
The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.
2019Eli Lilly
Loxo Oncology Acquired
Lilly bought the cancer-drug developer Loxo Oncology in 2019 for about $8 billion.
2020Bausch Health
SEC settlement closes the Philidor accounting case
On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.
2022Bausch Health
Bausch + Lomb listed on the NYSE and TSX
Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.
2022Eli Lilly
Mounjaro Approved
Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.
2023Eli Lilly
Zepbound Approved
Zepbound receives U.S. approval for chronic weight management.
2025Bausch Health
DURECT acquired and record annual revenue reported
Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…
2025Eli Lilly
Revenue Reaches $65.179B
Lilly reports $65.179B in 2025 revenue and $20.640B in net income.
2025Eli Lilly
First $1 Trillion Drugmaker
Lilly's market value crosses $1 trillion on November 21, 2025, a first for a healthcare company.
2026Bausch Health
RED-C trials miss endpoints and trigger a $1.4 billion charge
In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.
2026Bausch Health
Second-quarter 2026 revenue of $2.85 billion and raised guidance
Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.
2026Eli Lilly
Foundayo Approved
FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill for obesity, on April 1, 2026.
Acquisitions
Bausch Health
- DURECT Corporation2025$63M
- Shibo Zhenmei aesthetics distribution business2025Undisclosed
- Salix Pharmaceuticals2015$11.1B
- Bausch + Lomb Holdings2013$8.7B
- Ortho Dermatologics2011$345M
- Sanitas2011Undisclosed
Eli Lilly
- Morphic Holding2024$3.2B
- POINT Biopharma2023$1.4B
- Prevail Therapeutics2021$1B
- Loxo Oncology2019$8B
- Elizabeth Arden1971Undisclosed
Questions about Bausch Health vs Eli Lilly
Who is the CEO of Bausch Health Companies Inc. and Eli Lilly and Company?
Bausch Health Companies Inc. is led by Thomas J. Appio and Eli Lilly and Company is led by David A. Ricks. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bausch Health Companies Inc. founded vs Eli Lilly and Company?
Eli Lilly and Company was founded in 1876 — 118 years before Bausch Health Companies Inc., which was founded in 1994. Eli Lilly and Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bausch Health Companies Inc..
How many employees does Bausch Health Companies Inc. have compared to Eli Lilly and Company?
Bausch Health Companies Inc. employs approximately 20,300 people, while Eli Lilly and Company employs approximately 50,000. Eli Lilly and Company has the larger workforce at 50,000 employees, compared to Bausch Health Companies Inc.'s 20,300. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bausch Health Companies Inc. and Eli Lilly and Company headquartered?
Bausch Health Companies Inc. is headquartered in Canada and Eli Lilly and Company is headquartered in United States. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bausch Health Companies Inc. and Eli Lilly and Company?
Bausch Health Companies Inc. was founded by Eugene Melnyk, Milan Panic. Eli Lilly and Company was founded by Colonel Eli Lilly.
Which company has a longer operating history — Bausch Health Companies Inc. or Eli Lilly and Company?
Eli Lilly and Company has been operating for approximately 150 years, making it the more established of the two companies. Bausch Health Companies Inc. has been in operation for around 32 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bausch Health vs Eli Lilly overview